Hypermarcas (OTCMKTS:HYPMY) Shares Gap Up Following Dividend Announcement

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s share price gapped up before the market opened on Tuesday after the company announced a dividend. The stock had previously closed at $4.59, but opened at $5.02. Hypermarcas shares last traded at $5.02, with a volume of 25,000 shares. The newly announced dividend which will be paid on Friday, January 8th. Stockholders of record on Tuesday, July 1st will be issued a $0.0345 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a dividend yield of 2.81%. Hypermarcas's payout ratio is 45.83%.

Hypermarcas Stock Performance

The company has a market cap of $3.18 billion, a PE ratio of 20.91 and a beta of 0.79. The stock's 50-day simple moving average is $4.22 and its 200 day simple moving average is $3.57. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The company reported ($0.04) earnings per share for the quarter. The firm had revenue of $184.34 million during the quarter. Hypermarcas had a return on equity of 6.95% and a net margin of 12.51%.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.